GlaxoSmithKline (GSK) Q1 results ((£)):
Revenues: 9,090M (+18.7%); Pharmaceuticals: 4,396M (+5.7%); Vaccines: 1,805M (+18.6%); Consumer Healthcare : 2,862M (+44.5%).
Key product sales: Shingrix: 647M (+81%); Ellipta:
661M (+38%); Tivicay: 412M (+8%); Triumeq: 563M (-8%); Nucala: 210M
(+38%); Benlysta: 151M (+25%); Seretide/Advair: 395M (-19%);
Flixotide/Flovent: 123M (-16%); Ventolin: 253M (+3%); Augmentin: $169M
(+6%); Bexsero: 164M (+5%); Infanrix, Pediarix: 180M (-2%); Hepatitis:
213M (-11%).
Net Income: 1,565M (+88.6%); EPS: 0.32 (+88.2%); non-GAAP Net Income: 1,873M (+26.2%); non-GAAP EPS: 0.38 (+22.6%).
CF Ops: 965M (+45.6%).
2020 Guidance: Non-GAAP EPS to decline (1%) to (4%) at CER (unch).
Previously: GlaxoSmithKline EPS beats by £0.07, beats on revenue (April 29)
https://seekingalpha.com/news/3565946-glaxosmithkline-shingrix-sales-up-81-in-q1-guidance-affirmed
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.